prognosis

Last reviewed 01/2018

  • in 45% of patients there is symptomatic resolution within 20 days
  • in 25% of patients symptoms may persist for two months
  • study evidence revealed that psychiatric and neurological disorders persisted for more than two months in 30% of patients - however a causal link with mefloquine prophylaxis was not firmly established

Reference:

  • Prescribers' Journal (1999), 39 (3), 154-63.
  • Schlagenhauf P et al. The position of mefloquine as a 21st century malaria chemoprophylaxis.Malar J. 2010 Dec 9;9:357.